Paper Details

  1. Home
  2. Paper Details

First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.

Author: HellmichMartin, KuhrKathrin, LehmacherWalter, SrivastavaKunal, WirthDaniel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Melphalan and prednisone plus bortezomib (VMP) and melphalan and prednisone plus thalidomide (MPT) were more effective than melphalan and prednisone (MP) in treating multiple myeloma.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: The purpose of this study was to compare approved first-line therapies for patients with multiple myeloma. METHODS: A systematic literature search for phase III randomized controlled trials (RCTs) comparing first-line chemotherapies approved in Germany and recommended by guidelines at t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00228-015-1998-5

データ提供：米国国立医学図書館（NLM）

Comparing Therapies for Multiple Myeloma: A Head-to-Head Analysis

This study delves into the complex world of multiple myeloma, a type of blood cancer, focusing on the treatment options available for patients who are not eligible for stem cell transplantation. The authors use a systematic approach to compare the effectiveness of various first-line therapies, providing valuable insights for clinicians and patients making treatment decisions. It's like navigating a complex desert landscape, carefully evaluating the effectiveness of different paths leading to remission.

VMP and MPT Emerge as Promising Treatments

The study concludes that VMP (melphalan and prednisone plus bortezomib) and MPT (melphalan and prednisone plus thalidomide) are more effective than MP (melphalan and prednisone) in treating multiple myeloma. However, VMP appears to have a slight advantage in terms of response rate and adverse effects. It's like finding two different oases, each offering a unique path to recovery, with VMP potentially providing a slightly more comfortable and efficient route.

Navigating Treatment Options for Multiple Myeloma

This research offers valuable guidance for patients with multiple myeloma and their healthcare providers. It provides a comprehensive comparison of different treatment options, allowing for informed decisions. It's like having a detailed map of the desert, with clear markers indicating the benefits and risks of each path leading to remission. It's important to work with a healthcare professional to find the best treatment plan for your individual needs.

Dr. Camel's Conclusion

This study provides a valuable roadmap for navigating the treatment options for multiple myeloma. It underscores the importance of personalized care and informed decision-making in managing this complex disease. It's a testament to the ongoing pursuit of knowledge and innovation in cancer research, offering hope for those facing this challenging diagnosis. It's like finding a hidden oasis in the desert of cancer treatment, providing valuable insights and guidance for those seeking a path to recovery.
Date :
  1. Date Completed 2016-11-10
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26671239

DOI: Digital Object Identifier

10.1007/s00228-015-1998-5

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.